Health Economics›Breast cancer›Metastatic disease maintenance after first-line therapy

Metastatic disease maintenance after first-line therapy

Breast cancer · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	4.3 mo	23.7 mo	7	R 400 725 PFS proxy	1
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	11.9 mo	39.0 mo	18	R 532 973 PFS proxy	1
Exemestane monotherapy Variant #01	ER	R 2 846	90d	~3.8 mo	~45.1 mo	~2	~R 5 693 PFS proxy · indirect	10
Letrozole monotherapy Variant #01	ER	R 371	28d	~14.5 mo	~51.3 mo	~16	~R 5 934 PFS proxy · indirect	16
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	7.5 mo	32.3 mo	9	R 2 371 PFS proxy	2
Anastrozole monotherapy Variant #01	ER	R 159	28d	~13.8 mo	~42.7 mo	~16	~R 2 546 PFS proxy · indirect	12
Observation Partial	—	—	—	3.1 mo	23.5 mo	—	—	2

7 of 7 regimens shown